Investigators are conducting a real world, observational, prospective, multicenter study to better understand treatment for patients with MeVo and distal vessel occlusions in the U.S post publication of recent MeVO trials.
The primary objective of this study is to better understand the change in landscape, post clinical trials publication, of the management of medium vessel occlusion (MeVO) causing acute ischemic strokes (AIS) in the first 24 hours. This study will help us better understand the "equipoise" in the eyes of practicing physicians across the U.S. Investigators will include patients with MevO treated with mechanical thrombectomy as well as patients treated medically. Study design: This prospective, multicenter, observational study will include patients treated with best medical treatment (BMT) and patients who are treated endovascularly (endovascular treatment (EVT)). Patients who receive intra-arterial thrombolytics will also be included in the EVT group. In addition, patients who have received intravenous thrombolysis (tPA or tNK) will be included and patients who have not received any treatment. Patients presenting with symptoms of AIS in the anterior circulation secondary to MeVO will be screened at every participating site for inclusion in this pragmatic, observational, prospective registry. The definition of MeVO for this study includes the M2-M3 segments of the MCA, A2-A3 segments of the anterior cerebral artery (ACA), and P1-P3 segments of the posterior cerebral artery (PCA).
Study Type
OBSERVATIONAL
Enrollment
652
IU Health Neuroscience Center
Indianapolis, Indiana, United States
RECRUITINGClinical outcomes based on distribution of modified Rankin Scale score(mRS)
The modified Rankin Scale (a 7-point scoring system, 0 indicates no residual stroke symptoms and 6 represents death) is assessed through patient/caregiver interview by trained personnel.
Time frame: 3 months +/- 15 days
Utility weighted Modified Rankin scale (mRS) at 90 days
The Utility-Weighted Modified Rankin Scale (UW-mRS) is an advancement in the assessment of disability and functional independence for patients with neurological conditions. By incorporating patient preferences, it complements the traditional Modified Rankin Scale (mRS) by capturing individual preferences for specific health states.
Time frame: 3 months +/- 15 days
Excellent functional recovery (mRS 0-1)
Excellent functional recovery (mRS 0-1): Functional independence is identified by pooling all patients achieving a) no stroke deficits (mRS of 0), b)minimal stroke deficits without any functional limitations (mRS of 1)
Time frame: 3 months +/- 15 days
Functional independence (mRS 0-2)
Functional independence is identified by pooling all patients achieving a) no stroke deficits (mRS of 0), b) minimal stroke deficits without any functional limitations (mRS of 1) and c) functional limitations that do not interfere with independent living (mRS of 2) and illustrates being able to execute all day to day activities.
Time frame: 3 months +/- 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.